The Russell 3000 Index is a market-capitalization-weighted equity index that gives investors exposure to the entire US stock market. The index tracks the performance of the 3,000 largest US-traded stocks, which represent about 98% of all US incorporated equity securities.
The Russell 2000 Index, also market-capitalization-weighted, measures the performance of 2,000 small-cap US companies in the Russell 3000 Index.
READ: Zynerba tells FDA it should regulate CBD and cannabis-derived products like standard pharmaceuticals
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. About $9 trillion in assets are benchmarked against Russell’s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.
Zynerba, based in Devon, Pennsylvania, is currently developing Zygel, a CBD gel, to treat children aged three to 17 with Fragile X syndrome. Topline results are expected in the second half of 2019 from a clinical trial that evaluated the gel’s potency and safety. The company also has started a trial to assess how Zygel can treat the pediatric behavioral and emotional symptoms of 22q11.2 Deletion Syndrome.
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham